NCT06496958 Water Exchange and CO2 Insufflation With Abdominal Compression Device to Reduce Manual Assistance
| NCT ID | NCT06496958 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Evergreen General Hospital, Taiwan |
| Condition | Manual Pressure |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2024-09-02 |
| Primary Completion | 2026-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 400 participants in total. It began in 2024-09-02 with a primary completion date of 2026-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this trial is to evaluate whether water exchange colonoscopy and CO2-insufflation colonoscopy with an abdominal compression device (Maxbelt me3 type, Nippon Sigmax Co., Tokyo, Japan) can achieve a significantly lower proportion of patients requiring manual abdominal pressure during colonoscopic insertion compared with CO2 insufflation alone.
Eligibility Criteria
Inclusion Criteria: * Patients aged 45-80 years having an average risk for colorectal cancer who plan to undergo sedated outpatient colonoscopy for screening, surveillance, and those who have received a positive fecal immunochemical test result Exclusion Criteria: * Patients with hereditary colorectal cancer syndrome, including familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer (Lynch syndrome) * Patients with serrated polyposis syndrome * Patients with known or suspected inflammatory bowel disease * Patients with a history of colorectal cancer or other intra-abdominal malignancy * Patients with a history of colorectal resection * Patients with a history of abdominal aortic aneurysm, cirrhosis, ascites, or other severe comorbid illnesses * Patients with recent wounds or skin rash on the anterior abdominal wall and back * Patients with known ventral hernia * Patients with unsedated procedure * Patients with planned bidirectional endoscopy * Patients with body mass index \>35 kg/m2 * Patients with waist circumference \<55 cm or \>105 cm * Patients with known or suspected gastroparesis * Patients with planned therapeutic procedures (e.g., hemostasis, removal of a large polyp) * Patients with mental retardation * Pregnant women or those planning pregnancy * Patients unwilling to participate in the study
Contact & Investigator
Chi-Liang Cheng
PRINCIPAL INVESTIGATOR
Evergreen General Hospital
Frequently Asked Questions
Who can join the NCT06496958 clinical trial?
This trial is open to participants of all sexes, aged 45 Years or older, up to 80 Years, studying Manual Pressure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06496958 currently recruiting?
Yes, NCT06496958 is actively recruiting participants. Contact the research team at chiliang.cheng@gmail.com for enrollment information.
Where is the NCT06496958 trial being conducted?
This trial is being conducted at Kaohsiung City, Taiwan, Taoyuan, Taiwan.
Who is sponsoring the NCT06496958 clinical trial?
NCT06496958 is sponsored by Evergreen General Hospital, Taiwan. The principal investigator is Chi-Liang Cheng at Evergreen General Hospital. The trial plans to enroll 400 participants.